BioNTech stock forecast: Co-founders plan departure

BioNTech is a German biotechnology company whose shares came under pressure after weaker 2026 revenue guidance, a Q4 2025 net loss and the planned departure of its co-founders. Past performance is not a reliable indicator of future results. Explore third-party BNTX price targets and technicals.

By Dan Mitchellan hour ago

BioNTech flags displayed outside a modern building — Photo: Shutterstock

BioNTech SE (BNTX) is trading at €362.3 in afternoon trading on 17 March 2026, within an intraday range of €353–€362.3 and holding near the top of the day’s range. Past performance is not a reliable indicator of future results.

Sentiment has been shaped by three concurrent developments: the announcement on 10 March that co-founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to leave BioNTech to establish a new independent mRNA venture (Reuters, 10 March 2026); the company’s full-year 2026 revenue guidance of €2.0–€2.3 billion, which fell short of analyst consensus of approximately €2.75 billion (Yahoo Finance, 10 March 2026); and a Q4 2025 net loss of approximately €305 million.

BioNTech retains a cash position of approximately €17.2 billion and has outlined plans for 15 Phase 3 oncology trials by year-end, factors that analysts have cited alongside near-term execution and leadership transition risks (Investegate, 16 March 2026).

BioNTech stock forecast 2026–2030: Third-party price targets

As of 17 March 2026, third-party BioNTech stock predictions reflect a range of revised outlooks following the company’s Q4 2025 earnings release, below-consensus 2026 revenue guidance of €2–€2.3 billion, and the co-founders’ announced departure. All targets below are denominated in USD, reflecting analyst coverage of the Nasdaq-listed BNTX ADR.

Morgan Stanley (target trimmed)

Morgan Stanley analyst Terence Flynn cut the 12-month BNTX stock forecast to $125 from $134 while maintaining an Overweight rating. The revision follows the co-founders’ planned exit and management’s weaker-than-expected FY2026 revenue guidance, though the firm retains a constructive view on BioNTech’s late-stage oncology pipeline (GuruFocus, 11 March 2026).

BMO Capital Markets (target lowered)

BMO Capital Markets analyst Etzer Darout lowered the 12-month price target to $128 from $143 while maintaining an Outperform rating. The firm cites the CEO departure announcement as the primary catalyst for the reduction, with the lower target reflecting increased uncertainty around BioNTech’s near-term execution and leadership transition (Investing.com, 11 March 2026).

Citigroup (target reduced)

Citigroup analyst Geoff Meacham maintained a Buy rating on BNTX while cutting the 12-month price target to $130 from $145. The reduction reflects the shortfall against consensus revenue expectations amid the leadership transition, though the firm retains its constructive stance given BioNTech’s approximately €17.2 billion cash reserve and the breadth of its oncology pipeline (GuruFocus, 11 March 2026).

Clear Street (target trimmed)

Clear Street lowered its 12-month price target on BNTX to $167 from $181 while maintaining a Buy rating. The firm characterises the post-earnings sell-off as overdone and cites BioNTech’s strong balance sheet and 15 planned Phase 3 oncology trials as underpinning its higher relative target amid near-term leadership concerns (Investing.com, 10 March 2026).

Canaccord Genuity (target reiterated)

Canaccord Genuity reiterated a Buy rating on BNTX with a 12-month price target of $171.44, the highest among covering analysts, as of 11 March 2026. Analyst John Newman maintains the target amid confidence in BioNTech’s oncology development programme, with the firm’s stance unchanged despite the co-founder departure and the below-consensus FY2026 revenue guidance (MarketBeat, 11 March 2026).

Takeaway: post-earnings BioNTech stock predictions published in March 2026 have compressed the majority of active targets into a $125-$131 cluster, with Canaccord Genuity standing out at $171.44. Buy-type ratings remain dominant across all five covering analysts, while the shared rationale for downward revisions centres on the co-founder leadership transition and the €2–€2.3 billion revenue guidance shortfall.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

BNTX stock price: Technical overview

The BNTX stock price trades at €362.3 in afternoon trading on 17 March 2026, sitting just beneath a dense moving-average shelf where the 20/50/100/200-day SMAs converge in the €361–€372 range. Price is effectively pinned below the 20-day SMA (about €365) and the 50-day SMA (about €372), both of which register sell signals, while holding a marginal buy signal from the shorter 10-day SMA (about €354) immediately below.

Momentum is mixed to soft: the 14-day RSI sits at 46.7, a neutral reading consistent with consolidation rather than directional conviction, and the ADX at 29.0 indicates that an established trend is in force, though the prevailing direction remains to the downside given the bearish MA stack. The MACD level at -5.5 adds a modest sell-side lean to the oscillator picture.

To the upside, the first reference is the classic R1 at €392.2; a convincing daily close through that level would put the R2 area near €402 back in view. The Ichimoku base line at €362.9 sits almost exactly at the current price and represents an immediate cap worth watching on a closing basis.

On pullbacks, the classic pivot point at €378.9 offers an initial reference above, while to the downside the S1 at €369.0 provides the nearest classic support. Losing the S1 shelf would risk a move towards the S2 zone near €355.7, which roughly coincides with the 10-day SMA (about €354) and where buyers may look to re-engage. A sustained close beneath that area would expose the S3 level near €332.5 (TradingView, 17 March 2026).

This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

BioNTech share price history (2024–2026)

BioNTech’s BNTX first appeared in this dataset in March 2024, trading in the mid–€260s, and has broadly trended higher over the following two years.

BNTX’s stock price opened March 2024 near €266.70 and spent much of H1 2024 range-bound between €255 and €278, with a brief peak close of €278.25 on 28 March 2024. The stock drifted lower through summer 2024, touching a two-year dataset low close of €244.55 on 6 August 2024 amid a broader equity sell-off, before recovering steadily into year-end. BNTX closed 2024 at €296.10, up roughly 11% from that August trough.

The rally extended sharply into 2025, with the stock climbing from €297.30 at the start of January to a dataset high close of €392.60 on 5 January 2026, supported by growing confidence in BioNTech’s oncology pipeline and broader biotech sector strength. However, the stock gave back those gains in early March 2026 after the company’s Q4 2025 earnings release and co-founder departure announcement triggered a sharp sell-off, with BNTX briefly closing as low as €344.85 on 9 March 2026.

BNTX closed at €362.20 on 17 March 2026, approximately 7.7% down year to date from the 2 January 2026 close of €387.40, but roughly 36% higher than the 6 August 2024 trough close of €244.55.

Past performance is not a reliable indicator of future results.

BioNTech (BNTX): Capital.com analyst view

BioNTech’s BNTX has undergone a notable shift in the first quarter of 2026, moving from multi-month highs near €392 in early January to a more pressured range in the mid–€350s following the co-founders’ planned departure and below-consensus revenue guidance of €2.0–€2.3 billion for the full year. These developments have weighed on near-term sentiment, and the stock’s dense moving-average shelf between €361 and €372 now acts as overhead resistance. That said, BioNTech retains a substantial cash position of approximately €17.2 billion and has outlined 15 Phase 3 oncology trials by year-end, factors that some analysts view as supporting longer-term value, though execution risk under new leadership remains a genuine uncertainty.

The broader picture is one of transition: the post-Covid revenue normalisation that has compressed earnings in recent years may gradually give way to oncology-driven growth, but timelines are uncertain and clinical trial outcomes are inherently binary. Traders and investors may weigh the pipeline’s potential against the near-term guidance shortfall and leadership change, with outcomes capable of pulling the stock in either direction depending on how those factors develop.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Capital.com’s client sentiment for BioNTech CFDs

As of 17 March 2026, Capital.com client positioning in BioNTech CFDs shows 88.2% buyers and 11.8% sellers, putting buyers ahead by 76.5 percentage points and placing sentiment firmly in heavy-buy, one-sided-towards-longs territory. This snapshot reflects open positions on Capital.com and can change.

Summary – BioNTech 2026

As of 12:10pm UTC on 17 March 2026, BNTX was trading at €362.3, within an intraday range of €353–€362.3.
Technical indicators show price sitting just below a dense moving-average shelf at €361–€372, with the 14-day RSI at 46.7, in neutral territory and reflecting consolidation rather than clear directional momentum.
The MACD at -5.5 and the majority of medium-term SMAs registering sell signals add a modest bearish lean, while the ADX at 29.0 indicates that an established trend remains in force.
Key drivers include BioNTech’s below-consensus 2026 revenue guidance of €2.0–€2.3 billion, the co-founders’ planned departure to launch a new mRNA venture, and a Q4 2025 net loss of approximately €305 million.
Despite near-term headwinds, BioNTech holds approximately €17.2 billion in cash and has outlined 15 Phase 3 oncology trials by year-end, which some analysts cite as potential longer-term support.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most BioNTech stock?

BioNTech was founded by Prof. Ugur Sahin and Prof. Özlem Türeci, who have historically been among its most closely associated shareholders, alongside institutional investors and funds that hold positions through the NASDAQ-listed ADR. Ownership can change over time as insiders, funds and other shareholders adjust their stakes. For that reason, the largest current holder should be confirmed through the latest regulatory filings and company disclosures rather than treated as a fixed figure.

What is the 5 year BioNTech share price forecast?

A five-year BNTX stock forecast is highly uncertain because it depends on factors that are difficult to predict with confidence, including clinical trial results, regulatory outcomes, commercial execution and broader biotech market conditions. Third-party analyst targets usually focus on shorter time frames, often around 12 months, rather than five years. Longer-term projections should therefore be treated as speculative scenarios rather than reliable forecasts, especially for a biotechnology company in a transitional phase.

Is BioNTech a good stock to buy?

Whether BioNTech is a good stock to buy depends on an individual’s goals, time horizon and risk tolerance. The company has substantial cash reserves and a broad oncology pipeline, which some market participants see as supportive factors. At the same time, weaker revenue guidance, leadership transition and the binary nature of clinical development add uncertainty. That makes it important to view the stock in terms of both potential opportunities and risks, rather than through a simple good-or-bad lens.

Could BioNTech stock go up or down?

BioNTech stock could move in either direction, as its price remains sensitive to company-specific and sector-wide developments. Positive updates on oncology trials, regulatory progress or execution against strategy could support the share price. On the other hand, weaker financial performance, pipeline setbacks, leadership changes or softer biotech sentiment could weigh on it. Technical levels may help traders frame short-term scenarios, but they do not remove the underlying uncertainty around future price moves.

Should I invest in BioNTech stock?

Whether someone should invest in BioNTech is a personal decision and not something a general market article can answer. Any decision should take account of investment objectives, financial circumstances, tolerance for risk and time horizon. BioNTech offers exposure to a well-funded biotechnology business with an active oncology pipeline, but it also carries the risks associated with earnings pressure, leadership change and clinical uncertainty. Independent research is usually an important part of any assessment.

Can I trade BioNTech CFDs on Capital.com?

Yes, you can trade BioNTech CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.